Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer

Sukhontip Klahan; Wan-Chen Huang; Che-Mai Chang; Henry Sung-Ching Wong; Chi-Cheng Huang; Mei-Shin Wu; Yu-Chiao Lin; Hsing-Fang Lu; Ming-Feng Hou; Wei-Chiao Chang

doi:10.1016/j.phrs.2015.12.004

Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer

Pharmacol Res. 2016 Feb:104:31-7. doi: 10.1016/j.phrs.2015.12.004. Epub 2015 Dec 8.

Authors

Affiliations

¹ Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei City 110, Taiwan.
² Institute of Cellular and Organismic Biology, Academia Sinica, Taipei City 115, Taiwan.
³ Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei City 110, Taiwan; Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei City 110, Taiwan.
⁴ Department of Surgery, Cathay General Hospital, Taipei City 221, Taiwan; School of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan; School of Medicine, Taipei Medical University, Taipei City 110, Taiwan.
⁵ Department of General and Computational Linguistics, University of Tübingen, Germany.
⁶ Cancer Center, Kaohsiung Medical University hospital, Kaohsiung City 807, Taiwan.
⁷ Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei City 110, Taiwan; Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei City 110, Taiwan; Department of Pharmacy, Taipei Medical University-Wan Fang Hospital, Taipei City 116, Taiwan; Cancer Center, Kaohsiung Medical University hospital, Kaohsiung City 807, Taiwan; Comprehensive Cancer Center of Taipei Medical University, Taipei 110, Taiwan. Electronic address: wcc@tmu.edu.tw.

PMID: 26675717
DOI: 10.1016/j.phrs.2015.12.004

Abstract

Triple negative breast cancer (TNBC) accounts for approximately 15-20% of all types of breast cancer, and treatment is still limited. This type of breast cancer shows a high risk of recurrence, visceral metastasis, a worse prognosis, and shorter distant metastasis-free survival. Several studies have been reported that genetics factors are associated with breast cancer disease progression and patients' survival. In this study, we combined Taiwanese microarray data from the GEO database and The Cancer Genome Atlas (TCGA) database to study the role of Integrin Beta1 (ITGB1) in TNBC. Two triple negative breast cancer cell lines (MDA-MB-231; MDA-MB-468) were used to validate the functions of ITGB1. We found that a higher ITGB1 gene expression level was associated to lower survival. Silencing of ITGB1 inhibited TNBC cell migration, invasion and store-operated calcium influx. Our study provided a potential candidate biomarker for breast cancer cells migration, invasion and TNBC patients' survival.

Keywords: Cell migration; ITGB1; Store-operated calcium channel; Triple negative breast cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Asian People / genetics
Biomarkers, Tumor / genetics*
Calcium / metabolism
Cell Cycle
Cell Line, Tumor
Cell Movement
Cell Proliferation
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic*
Gene Silencing
Humans
Integrin beta1 / genetics*
Integrin beta1 / metabolism
Prognosis
RNA, Messenger / metabolism
RNA, Small Interfering / genetics
Taiwan
Triple Negative Breast Neoplasms / genetics*

Substances

Biomarkers, Tumor
Integrin beta1
RNA, Messenger
RNA, Small Interfering
Calcium